AGM/EGMApr 29, 2026, 04:38 PM
LCTX Annual Meeting June 10, 2026; Elects 7 Directors, Ratifies Auditor
AI Summary
Lineage Cell Therapeutics, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders, scheduled for June 10, 2026. Shareholders will vote on the election of seven directors, the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory vote on named executive officer compensation. The filing also details non-employee director compensation, including annual cash fees and stock option grants, and outlines the company's corporate governance practices.
Key Highlights
- Annual Meeting of Shareholders scheduled for June 10, 2026.
- Shareholders to elect seven directors to the Board.
- Nominees include Michael H. Mulroy, Dipti Amin, Deborah Andrews, Neal C. Bradsher, Brian M. Culley, Anula Jayasuriya, and Angus C. Russell.
- Proposal to ratify Baker Tilly US, LLP as independent auditor for 2026.
- Advisory vote on compensation paid to named executive officers.
- Non-employee directors receive annual cash fees, with Board Chair receiving $90,000.
- Non-employee directors receive an annual stock option grant for 75,000 common shares.
- Six of the seven director nominees are considered independent.
Price Impact
More from LCTX